Topics

Fibrogen, AstraZeneca confirm roxadustat's heart safety months after confusing first readout

11:31 EST 8 Nov 2019 | BioPharmaDive

Pooled data from seven studies showed the red blood cell-boosting pill to be as safe as placebo and safer than Epogen on some heart measures in kidney disease patients.

Original Article: Fibrogen, AstraZeneca confirm roxadustat's heart safety months after confusing first readout

NEXT ARTICLE

More From BioPortfolio on "Fibrogen, AstraZeneca confirm roxadustat's heart safety months after confusing first readout"

Quick Search

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Renal disease
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...